Clinical Trials DEA Safety THC 
Cannabis Law Report
NOVEMBER 22, 2019
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. Orphan Drug Designation?
Veriheal
APRIL 11, 2022
Drug Enforcement Agency (DEA). According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”. Groff confirmed that it had completed its first batch of medicinal-grade cannabis for research purposes on Feb. federal law.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpeedWeed
MARCH 18, 2021
One group self-administered cannabis with 12% THC over three weeks. Another group received an 11% CBD product with minimal THC. A third group received a balanced THC-CBD product, with roughly 8% THC and 8% CBD. for the production of cannabis used in federally-regulated clinical trials.
Cannabis Law Report
JUNE 4, 2021
With Delta 8, one is not going to have an anxious or paranoia episode as can be common for newcomers to marijuana forms of cannabis – especially with high concentration of THC that is readily available today. Delta 8-THC is a psychoactive cannabinoid, just like Delta 9-THC, and legislators should regulate it as such.
Veriheal
AUGUST 31, 2020
Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Previously a Schedule I substance, hemp was reclassified; hemp has extremely low levels of THC (less than 0.3%).
Cannabis Law Report
JANUARY 11, 2019
Accordingly, the Drug Enforcement Administration (DEA) no longer has any claim to interfere with the interstate commerce of hemp products, so as long as the THC level is at or below 0.3%. While the DEA is now officially out of the hemp regulation business, the U.S. The FDA’s position on CBD is unsettled and unsupported by law.
Canna Law Blog
NOVEMBER 6, 2021
To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. That power is typically delegated to the DEA.
Expert insights. Personalized for you.
66 
Let's personalize your content